Patents by Inventor Youssef Jounaidi

Youssef Jounaidi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
    Patent number: 12202856
    Abstract: Fusion proteins comprising IL2 and IL2R? (e.g., CIRB), IL2, IL2R? and IL21R (e.g., CIRB21), and/or comprising IL2, IL2R?, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, e.g., to treat subjects with cancer; and regulatory T cells (T-regs) that express a fusion protein comprising IL2, IL2R?, and CD28 and methods of use thereof, e.g., to treat subjects with autoimmune disease or GVHD.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 21, 2025
    Assignee: The General Hospital Corporation
    Inventors: Youssef Jounaidi, Stuart Forman, Keith Miller, Joseph F. Cotten
  • IL2 TETHERED TO ITS RECEPTOR IL2RBETA AND PORE-FORMING PROTEINS AS A PLATFORM TO ENHANCE IMMUNE CELL ACTIVITY
    Publication number: 20240207405
    Abstract: Described herein are immune cells (e.g., natural killer (NK), T cells) expressing a chimeric protein comprising IL2 and IL2R? (e.g., CIRB), a chimeric protein comprising IL2, IL2R? and IL21R (e.g., CIRB21), a chimera protein comprising IL2, IL2R?, and CD28 (e.g., CIRB28), or a combination thereof, and comprising a nucleic acid encoding a pore-forming protein, and methods of using such immune cells for treating a subject (e.g., a subject having cancer, graft-versus-host disease (GVHD), or an autoimmune disease. Expression of the pore-forming protein can be induced to promote destruction of immune cells expressing CIRB, CIRB21, CIRB28, or a combination thereof.
    Type: Application
    Filed: April 27, 2022
    Publication date: June 27, 2024
    Inventors: Sumei Chen, Joseph F. Cotten, Youssef Jounaidi, Keith Miller, Stuart Forman
  • TETHERED INTERLEUKIN-2 TO ITS RECEPTOR IL-2RBETA, A PLATFORM TO ENHANCE NATURAL KILLER AND REGULATORY T CELL ACTIVITY
    Publication number: 20200316118
    Abstract: Fusion proteins comprising IL2 and IL2R? (e.g., CIRB), IL2, IL2R? and IL21R (e.g., CIRB21), and/or comprising IL2, IL2R?, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, e.g., to treat subjects with cancer; and regulatory T cells (T-regs) that express a fusion protein comprising IL2, IL2R?, and CD28 and methods of use thereof, e.g., to treat subjects with autoimmune disease or GVHD.
    Type: Application
    Filed: May 19, 2017
    Publication date: October 8, 2020
    Inventors: Youssef Jounaidi, Stuart Forman, Keith Miller, Joseph F. Cotten